As an Associate Partner in L2 Consulting, Jean-Marie Houle possesses a fusion of strong scientific leadership and credibility together with senior management skills as exercised in the pharma, biotech and contract research sectors of industry.  A Pharmacist by training with graduate studies in pharmacokinetics and cancer treatment, he is recognized for his expertise and experience in drug development and his contributions to corporate growth. A subject matter expert in the fields of pharmacology, pharmacokinetics and drug metabolism, numerous drug candidates have benefited from his scientific input as they progress to the market or to advanced stages of development. 

In recent job roles, he contributed to successful First-In-Human transitions as well as Phase II Proof-Of-Concept.  He currently supports emerging biotech companies on a consulting basis.  He was Vice-President and Managing Director of the Quintiles Phase I Unit in London, after having served CPR Pharma Services Pty Ltd (Australia) and PharmaNet (Canada) Inc. (now Inventiv Health Clinique Inc.) in senior operational/scientific roles.  Prior, he was VP of R&D in a biotechnology company in Montreal, consultant for several pharma/biotech companies in various therapeutic areas, Director of Pharmacokinetics/Clinical Pharmacology for 6 years at QLT (Vancouver, Canada, NASDAQ:QLT) where he played an important role in the successful regulatory approval of Visudyne® in US, Canada, EU and Japan.  Before QLT, he was Scientific Director in a fast-growing Clinical Research Organisation.

Jean-Marie Houle PhD